Registry of Treatment Outcomes in a non-study population of Symptomatic Metastasized Castration Resistant Prostate Cancer (mCRPC) Patients Treated with Radium-223 (ROTOR-registry).

Registry of Treatment Outcomes in a non-study population of Symptomatic Metastasized Castration Resistant Prostate Cancer (mCRPC) Patients Treated with Radium-223 (ROTOR-registry). - Radium-223 in mCRPC patients registry/ROTOR-registry

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON55579

Enrollment

100

Registered

2015-10-14

Start date

2015-12-10

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bone metastases Prostate cancer

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - At the physicians discretion - Written informed consent - Age 18 year of older

Exclusion criteria

Exclusion criteria: - At the physicians discretion

Design outcomes

Primary

Measure	Time frame
To evaluate the efficacy of Radium-223 treatment in a non-study population by effects on Symptomatic Skeletal Event (SSE)	—

Secondary

Measure	Time frame
To Evaluate Radium-223 treatment efficacy by patient reported analgesic use and pain outcome.	—

Countries

Netherlands

Outcome results